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| INTRODUCTION
Hirudin is the most potent naturally-occurring direct thrombin inhibitor (DTI), and the first parenteral anticoagulant used on humans.
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Originally derived from the medicinal leech (Hirudo medicinalis), it consists of a 65 amino acids polypeptide chain, forming non-covalent, equimolar, non-reversible 1:1 complexes with α thrombin. 1 When hirudin-bound, thrombin-catalyzed reactions and fibrinogen clotting are blocked, and coagulation is subsequently inhibited. 2 Hirudin was previously produced in limited amounts, however, recombinant DNA technology allowed its mass production. 3 These recombinant forms bind bivalent to thrombin with pharmacokinetic and anticoagulant profile similar to that of the native form. 4 Hematoma, a localized mass of extravagated blood that is relatively or completely confined within an organ or tissue, is a common result of physical trauma. 5 Topical applications are frequently used to treat subdermal hematomas and accompanying symptoms, and include anti-inflammatory and antioedematous treatments like heparin and heparinoid gels and creams.
Heparins have proven to be an effective topical treatment for patients with hematomas due to blunt injuries. 6 However, r-hirudin proved to be more effective than heparin in percutaneous penetration following topical application due to its relatively small size. 7, 8 Percutaneous penetration of hirudin was demonstrated in pigs and guinea pigs. 9, 10 Furthermore, the thrombolytic effect of topically administered r-hirudin was shown in a rabbit model for thrombosis.
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There are several other benefits to the alternative use of hirudin; it does not require a cofactor to produce a coagulant effect, and it does not induce platelet activation. Unlike heparin, hirudin cannot be bound and inactivated by platelet factors and other substances, and its small size also allows it to block thrombus-bound thrombin which is inaccessible to heparin-antithrombin complexes. The study consisted of a total of four visits. The primary and co-investigators determined subject eligibility during the screening visit (defined as day 1). Eligible patients were randomized, using a simple randomization scheme (1:1), to receive either hirudin gel (Hirudo medicinalis extract 1120 IU/100 g, Thrombexx, Minapharm
| MATERIALS AND METHODS

| Study design
Pharmaceutical, Heliopolis, CAI, Egypt) or placebo. All randomization procedures were conducted by the study monitors. Our investigation adopted a double-blind design to limit bias; only the study monitors and statistician were aware of treatment allocation. During visits 2-4 (days 4, 8, and 16) patients were provided with their respective intervention in the dose prescribed, and target parameters were assessed.
| Inclusion and exclusion criteria
The study population comprised male and female adult patients 
| Treatments
Study medications and the placebo were packaged in tubes of identical appearance. These tubes were subsequently numbered for each patient according to the randomization schedule. Patients were instructed to apply 2-3 cm of r-hirudin gel 2-3 times daily, for a total of 32-48 administrations throughout the 16-day study period. Due to ethical considerations, treatment with concomitant analgesics/ NSAIDs was permitted, when required. Diclofenac sodium and paracetamol were prescribed for patients needing additional treatment.
| Study outcomes
The primary endpoints were assessed during each study visit, and 
| Statistical analysis
The safety population included all randomized patients who had Descriptive summary statistics were provided for quantitative data, and were summarized using count, mean with 95% confidence interval (CI), standard deviation (SD), median, minimum, and maximum. Cochran's Q tests were used to estimate the paired changes in qualitative variables throughout the study. Any relative difference in the time to complete resolution was assessed using the Kaplan-Meier estimator. All statistical tests were performed at a two tailed 5% level of significance, using SPSS version 18 (IBM, Chicago, IL, USA).
| RESULTS
| Patient status and characteristics
A flow diagram of the current study is shown in Figure 1 . The study population comprised 200 patients, diagnosed with at least one subdermal hematoma. One patient committed a major protocol violation (patient was below the specified inclusion age range; 20-60 years).
The remaining 199 patients, presenting with 200 hematomas (one patient had two hematomas) were subsequently randomized; 49.5%
of cases (n = 99) were allocated to the r-hirudin treatment group (arm 1), and 50.5% of cases (n = 101) in the placebo group (arm 2). Both Table 1 . For the treatment arm of the study, 48.5% of subjects were female (n = 48) and the mean age of patients was 35.7 ± 12.3 years.
As for the placebo arm, 32.7% of patients were female (n = 33), and the mean age of constituents was 34.1 ± 11.9 years. While there were no significant age differences between the two arms of the study, a significant gender difference was observed (p < 0.05). No significant differences in the position of musculoskeletal injuries were observed, with the majority of participants presenting with lower limb trauma (r-hirudin arm: n = 78, 78.8% vs. placebo arm: n = 87, 86.1%; Table 1 ).
Moreover, no significant inter-arm differences, in regards to the color of hematomas and the concomitantly prescribed analgesic, were noted. However, significant differences in mean hematoma size and mean pain intensity were observed at baseline; the r-hirudin treated T
; P < .05), whilst the placebo group reported a higher mean pain intensity (r-hirudin:
6.88 ± 0.16 cm vs placebo: 7.43 ± 0.15 cm; P < .01; Table 1 ). Although there was a statistical significant difference in pain intensity between the two groups, it was of no clinical significance. For the aforementioned variables, the change from baseline values was used to determine efficacy.
| Change in hematoma size
A significant baseline-to-end of study reduction in mean hematoma size was observed in the r-hirudin cohort (P < .001). While a significant decrease was also observed in the placebo group (P < .001), it was less pronounced; significant inter-group differences were noted.
Reductions in hematoma size were initially observed on day 4, with r-hirudin administered patients exhibiting a significantly larger reduction in mean hematoma size (r-hirudin: 87.0 ± 20.9% vs placebo: 52.8 ± 52.0%; P < .001; Figure 2A ). r-hirudin treated patients continued to exhibit significantly larger declines in hematoma size at day 8 (r-hirudin: 99.0 ± 4.5% vs placebo: 82.9 ± 30.8%; P < .001; Figure 2A ), and at the end of study (r-hirudin: 99.9 ± 0.6% vs. placebo:
96.6 ± 7.3%, P < .001; Figure 2A ).
| Change in hematoma color
Inter-arm differences in hematoma color were initially observed at day 4, and a statistically higher number of patients receiving r-hirudin presented with faint hematomas (r-hirudin: n = 76, 76.8% vs. placebo: n = 61, 60.4%; P < .05; Figure 2B ). These inter-group differences remained significant at day 8, with 96% (n = 95) and 62.4%
(n = 63) of r-hirudin and placebo administered patients exhibiting faint hematomas, respectively (P < .001; Figure 2B ). By study end, a significantly higher number of r-hirudin administered patients presented with faint hematomas, when compared to control (r-hirudin: n = 98, 99% vs placebo: n = 69, 71.9%; P < .001; Figure 2B ). Overall, significant baseline-to-end of study changes in hematoma color were observed for r-hirudin (P < .001) as well as placebo administered subjects (P < .001).
| Resolution of hematomas
Significant inter-group differences in the number of subjects who had achieved complete hematoma resolution were observed throughout the treatment period, with a statistically higher number of patients in the r-hirudin arm reaching this therapeutic target. This difference favoring the treatment arm was initially observed at day 4, with a higher proportion of r-hirudin administered with resolved hematomas (r-hirudin: n = 42, 42.4% vs placebo: n = 13, 12.9%; P < .001; Figure 2C ). By day 8, the majority of patients in the r-hirudin arm achieved resolution (r-hirudin: n = 93, 93.9%, placebo: n = 39, 38.6%; P < 0.001; Figure 2C ), and Inter-group differences remained significant until the final visit (r-hirudin: n = 97, 98% vs placebo: n = 69, 71.9%; P < .001; Figure 2C ). While the number of patients achieving this therapeutic target was distinctly higher for the treatment arm, significant baseline-to-end of study changes in hematoma status were observed in both groups (r-hirudin: P < .001 vs placebo: P < .001).
| Time to complete resolution of hematomas
Median time to resolution for r-hirudin administered patients was significantly lower in the treatment arm (r-hirudin: 8 days vs placebo: 
| Change in pain intensity (improvement of flare)
r-hirudin administered patients exhibited a significant baseline-toend of study reduction in mean VAS scores (P < .001). While placebo administered patients also displayed significant reductions (P < .001), the decline observed in the treatment group was significantly larger throughout the study. Reductions in VAS scores were initially observed at day 4 with r-hirudin administered patients exhibiting significantly higher reductions (r-hirudin: 43.5 ± 16.9% vs. placebo: 30.4 ± 17.3%; P < .001; Figure 3A ). Further decline in mean VAS scores was observed during day 8 (r-hirudin: 70.9 ± 16.3% vs.
placebo: 54.7 ± 21.5%; Figure 3A ) and at the end of study (r-hirudin:
93.6 ± 12.4% vs placebo: 78.6 ± 21.6%; Figure 3A) . The difference favoring the r-hirudin cohort of patients was statistically significant during both visits (day 8: P < .001; day 16: P < .001).
| Resolution of hematoma-associated edemas
A statistically significant number of r-hirudin administered patients achieved complete resolution of edemas by study end (P < .001). While a significant change in edema status was also observed in the control group, the proportion of patients with resolved hematomas was significantly larger in the r-hirudin cohort. Resolution of edemas was initially observed at day 4, with a significantly larger number of patients in the r-hirudin arm achieving this therapeutic goal (r-hirudin: n = 30, 30.3%
vs placebo: n = 11, 10.9%; P < .01; Figure 3B ). This trend was consistent throughout the study, with a statistically higher number of treatment administered subjects achieving edema resolution at day 8 (r-hirudin: n = 92, 92.9% vs placebo: n = 34, 33.7%; P < .001; Figure 3B ) and 16 (r-hirudin: n = 98, 99% vs. placebo: n = 48, 50%; P < .001; Figure 3B ).
| Safety and tolerability
Data from safety population (n = 200) was included in this analysis.
The overall treatment exposure was 16 days. None of the patients in either arm exhibited any AEs, including allergic cutaneous reactions or local skin events. Furthermore, no SAEs occurred during the study and/or follow-up period. Hirudin gel (1120 IU/100 g), applied 2-3 times daily, was well tolerated.
| DISCUSSION
Treatments of hematomas include the use of analgesics, antiinflammatory, and in some cases, anticoagulants. The use of topical anticoagulants such as heparin gels has been comprehensively investigated, and the safety, tolerability, as well as the symptom reducing effects for superficial vein thrombosis. [12] [13] [14] However, some studies have demonstrated a limited systemic anticoagulant effect of topically administrated heparin, which is due to the large molecular weight of heparin, its negative charge, and hydrophilic nature.
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In contrast, hirudin binds directly to thrombin without a co-factor to exert its anticoagulant effect. 15 Moreover, hirudin is highly specific, and acts on both soluble and fibrin-bound thrombin to produce a sustained thrombolytic effect that lasts beyond its plasma clearance. [16] [17] [18] r-hirudin is relatively small when compared to heparin, 7, 8 and thus has the ability to percutaneous penetration following topical application. The antithrombotic effect of topically administered r-hirudin has been clinically assessed in patients with extravasations caused by internal fistula during maintaining-blood purification treatment, a curative effect was observed following a 7-day hirudin cream treatment, with or without ultrashort wave therapy and low-frequency magnetic therapy. 19 Moreover, in an investigation by Stamenova et al. (2001) , local application of a Hirudo medicinalis extract-containing cream produced a significant and rapid alleviation of pain in patients affected with bruises, with or without hematomas.
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The aim of our study was to assess the efficacy and safety of r-hirudin gel in patients with hematomas. r-hirudin administeredpatients demonstrated significantly larger reductions in mean hematoma size when compared to their placebo administered counterparts at the study end. Moreover, topical treatment with r-hirudin resulted in a more pronounced improvement in flare, a finding that is consistent with previous reports. 9 A significantly higher number of subjects in the r-hirudin cohort exhibited faint bruises following allocation of treatment, and a larger proportion of these patients achieved complete resolution of hematomas and edemas by end of study. These improvements were observed as early as day 4 with r-hirudin. r-hirudin gel showed a faster resolution of hematomas, with inter-arm comparisons revealing a statistically shorter median time in the treatment arm.
The study duration (16 days) was sufficient to evaluate the safety of topically applied r-hirudin. r-hirudin gel was well tolerated, and no one study where a hirudin-containing ointment was administered for 4.5 months. 20 One disadvantage of hirudin is that it is highly immunogenic when taken intravenously, 21 thus topical administration limits systemic exposure of r-hirudin. However, some studies showed that r-hirudin has weak immunogenicity. 15, 22, 23 There are several limitations faced our current investigation.
Although the study was a double-blind, there was a baseline disparity between the two arms. In addition to the significant differences in gender composition for the two arms, r-hirudin administered patients also had, on average, larger hematomas when compared to placebo. These initial dissimilarities may play a role in the observed inter-arm differences for these variables. Furthermore, due to ethical concerns, the use of a concomitant analgesic was permitted, if needed by patients.
The effect of topical hirudin administration on pain intensity is likely to have been confounded by the use of these analgesics.
In our study the majority of patients presented with hematomas While the use of parenteral r-hirudin has been extensively investigated, the number of studies assessing the efficacy and safety of topical r-hirudin are limited. Findings from the current study suggest that topical 1120 IU/100 g r-hirudin gel is an effective approach for the symptomatic treatment of hematomas.
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